Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vebicorvir · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | VBR 300 mg solution containing 2 µCi \[14C\]VBR |
| Name | Type | Description |
|---|---|---|
| Vebicorvir (VBR) | DRUG | 300mg Vebicovir containing 2 µCi \[14C\]VBR. |
* Consent * Male between 18 and 55 years of age (inclusive) at the time of Screening * Body mass index (BMI) between ≥18.0 kg/m2 and ≤32.0 kg/m2 at Screening; body weight between ≥55.0 kg and ≤100.0 kg at Screening * Considered to be in good health by the Investigator Exclusion Criteria: * History...
Vebicorvir is an investigational small molecule being developed for the treatment of chronic Hepatitis B. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied to evaluate its absorption and metabolism in the body.
Vebicorvir is being developed by Assembly Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ASMB. The company is conducting clinical research on this investigational drug for chronic Hepatitis B.
Vebicorvir is currently in Phase 1 clinical development. It is an investigational drug and has not yet received FDA approval. The drug is being studied for the treatment of chronic Hepatitis B, and its safety and pharmacokinetics are being evaluated in early-stage trials.
Vebicorvir has one completed Phase 1 clinical trial registered under NCT04637139. This study evaluated the mass balance absorption and metabolism of Vebicorvir in healthy male volunteers. The trial enrolled 6 participants and was conducted in the United States.
No, Vebicorvir is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for chronic Hepatitis B. The drug has not completed the clinical trials necessary to establish its safety and efficacy for regulatory approval.